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SUMMARY
USP2a isadeubiquitinase responsible for stabilization
of cyclin D1, a crucial regulator of cell-cycle pro-
gression and a proto-oncoprotein overexpressed in
numerous cancer types. Here we report that litho-
cholic acid (LCA) derivatives are inhibitors of USP
proteins, including USP2a. The most potent LCA de-
rivative, LCA hydroxyamide (LCAHA), inhibits USP2a,
leading to a significant Akt/GSK3b-independent
destabilization of cyclin D1, but does not change the
expression of p27. This leads to the defects in cell-cy-
cleprogression.Asa result, LCAHA inhibits thegrowth
of cyclin D1-expressing, but not cyclin D1-negative
cells, independently of the p53 status. We show that
LCA derivatives may be considered as future thera-
peutics for the treatment of cyclin D1-addicted p53-
expressing and p53-defective cancer types.
INTRODUCTION
Lithocholic acid (LCA) is a representative of secondary bile acids.
It is produced by intestinal bacteria from chenodeoxycholic acid,
which is one of the final products of cholesterol catabolism
(Staels and Fonseca, 2009). The primary role of bile acids is to
promote the absorption of lipids, but they are also involved in
the regulation of cholesterol and glucose homeostasis by the
means of endocrine mechanisms (Houten et al., 2006). The bio-
logical activity of secondary bile acids in relation to carcinogen-
esis has been investigated previously (Nagengast et al., 1995).
On one hand, an increased level of free secondary bile acids
was shown to correlate with the incidence of colon cancer,
and cell- and animal-based studies showed that secondary
bile acids act as tumor promoters (Bernstein et al., 2011; Far-
hana et al., 2016; Prasad et al., 2014). On the other hand, cyto-
toxic properties of LCA and its diverse derivatives have been
utilized in multiple approaches, aimed at the discovery of anti-
tumor drugs. LCA became one of the new scaffolds in this area
due to its biological activity, natural occurrence, and uncommon
toxicity profile in that although it is toxic for small animals, it is
safe for humans (Hofmann, 2004). Goldberg et al. (2011) re-
ported that LCA induces apoptosis in neuroblastoma cell lines
in a concentration range non-toxic to primary neurons, pointing
to the selectivity of the compound toward cancer cells.
The toxicity of bile acids against hepatocyte- and colonocyte-
derived cancer cell lines was widely studied in the past. Bile
acids, including LCA, have been shown to enantioselectively
induce apoptosis in human colorectal carcinoma and colorectal
adenocarcinoma cell lines, yet the effective concentration of
tested compounds was in a three-digit micromolar range (Ka-
tona et al., 2009). Of note, previous studies on the toxicity of de-
oxycholic acid and its derivatives were also performed with the
use of high, submillimolar concentrations, suggesting rather
weak bioactivity of tested compounds (Payne et al., 2005;
Wachs et al., 2005; Yui et al., 2005). The improvement of anti-
cancer properties of bile acid-derived compounds was only
recently achieved by introducing diverse structural modifica-
tions, thus obtaining molecules active at low-micromolar con-
centrations (Ma´jer et al., 2014; Sharma et al., 2010; Singh
et al., 2015). Following this trend, we investigated whether
more potent LCA derivatives may be obtained. We prepared a
panel of LCA modifications and evaluated their biological prop-
erties in a set of in vitro tests. Our study identified growth-inhib-
itory properties of LCA derivative LCAHA toward HCT116 cells,
unexpectedly revealing a cyclin D1 degradation-dependent
mechanism of action resulting from a direct inhibition of ubiqui-
tin-specific peptidase 2a (USP2a).
RESULTS
The Design of LCA Derivatives
In a search for new small-molecule candidates for targeting co-
lon cancer, we have synthesized a panel of LCA derivatives,
following earlier discoveries by Katona et al. (2009) and Vogel
et al. (2012). We synthesized a variety of C3, C24, and double
C3/C24modifications of LCA, introducing small moieties (amine,
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carbonyl, aminonitryl) or lowmolecular weight esters in positions
R1 and R4 (Table 1). Electronegative atomswere introduced with
the aim of increasing the solubility of the compounds. In addition,
by introducing the oxygen or nitrogen atoms to the steroid struc-
ture, we aimed at increasing the number of possible interactions
with potential protein targets, consequently improving the
biological activity of LCA. We also modified steroid carbons
C3 and C24 with larger, standard solubilizing groups, such as
amino ester hydrochloride, morpholine, or N-methylglucos-
amine. Additionally we tested the influence of hydroxyl groups
at positions R2 and R3 on the biological activity by evaluating
certain commercially available bile acids, namely ursodeoxy-
cholic acid, cholic acid, and taurocholic acid.
LCA Derivatives Affect the Growth Rate and Survival of
HCT116 p53wt and p53–/– Cells
To test the biological activity of the compounds, we performed
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) and lactate dehydrogenase (LDH) release assays. In addi-
tion, the importance of p53 status was evaluated by the use of
two variants of HCT116 cells: HCT116 p53wt (wild-type) and
HCT116 p53/. To track not only the toxic (lethal) but also
growth-inhibitory (GI) effect in the MTT assay, we treated the
cells for 6 days. In the experiment the toxic effect, but not the
GI effect, was expected to be accompanied by LDH release.
All tested compounds presented lethal effect with LD50 values
in the range 7–50 mM (for six compounds) or above 50 mM (for five
compounds) (Table 2 and Figure S1). LD50 values were not
dependent on the status of p53.
For one LCA derivative, LCAHA, a biphasic response was
observed for both cell types tested: a low-concentration GI
effect and a high-concentration toxic effect (Figure 1A). LDH
release was observed only at the concentrations corresponding
to the high-concentration toxic effect (Figure 1B). TheGI50 values
calculated from MTT results were below 1 mM for both cell lines
(Table 2) and the growth of cells was inhibited by about 60% in
Table 1. Lithocholic Acid Derivatives Tested in This Study
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the concentration range 2–20 mM (Figure 1A). For the lethal ef-
fect, LD50 values were above 25 mM for both cell lines, giving
selectivity of the GI effect over the lethal effect of 31.9-fold for
p53wt and 27.6-fold for p53/ cells (Table 2).
To evaluate whether the observed effects are accompanied by
the induction of apoptosis, we examined the activation of cas-
pases 3 and 7 in HCT116 p53wt cells. A weak and non-significant
increase of caspase activity was detected in the cells treated
with 1 or 5 mM LCAHA for 48 or 72 hr. Only at 10 mM LCAHA
was the increase of caspase activity significant (Figure 1C).
Thus, apoptosis is not efficiently induced in the GI concentration
range of the compound. Treatment with staurosporine, a known
inducer of apoptosis, led to a strong increase of the activity of
caspases 3 and 7 (Figure 1C).
LCAHA Arrests HCT116 Cells in G0/G1
Low concentrations of LCAHA inhibit the growth of HCT116 cells
without affecting their survival. To investigate this effect, we
analyzed the cell-cycle distribution. Cells treated for 48 hr with
LCAHA or DMSO were pulse-labeled with BrdU for 1 hr and
stained with fluorescein isothiocyanate (FITC)-anti-bromodeox-
yuridine (BrdU)antibodyandpropidium iodide (PI). Flowcytometry
analysis revealedmild, but significantG0/G1arrestofbothHCT116
p53wt and HCT116 p53/cells treated with 5 or 10 mM LCAHA
(Figure 1D). The analysis of BrdU incorporation revealed a dose-
dependent decrease in the rate of DNA synthesis in LCAHA-
treated cells (Figure 1E). This suggests that besides G0/G1 arrest,
LCAHA also affects the progression through the S phase.
To verify this, we pulse-labeled HCT116 p53wt cells treated
with LCAHA for 48 hr for 1 hr with BrdU and harvested or cultured
them for an additional 3, 6, or 9 hr. To track the progression
through the S phase and G0/G1 arrest precisely, we analyzed
FITC-positive and -negative cells separately for cell-cycle distri-
bution using ModFit LT software. FITC-positive cells repre-
sented the cells that incorporated BrdU (the population in the
S phase during pulse-labeling that progressed toward G2/M in
succeeding hours), and FITC-negative cells represented the
cells that did not incorporate BrdU (the population that was
either in G0/G1 or G2/M phase during pulse-labeling and entered
S phase or divided in succeeding hours).
As expected, the majority of BrdU+ cells were in the S phase
at time point t0, and the majority of BrdU
 cells were in G0/G1 or
G2/M phases (Figure 1F). Nine hours later only 23% of BrdU
+
cells treated with DMSO were still in the S phase and more
than 50% of cells had finished the cell cycle and were located
in G0/G1 phase (Figure 1F, top panel). The treatment with
LCAHA dose-dependently inhibited the transition of BrdU+ cells
through the S phase, as evidenced by the significantly higher
proportion of cells remaining in the S phase (up to 56% at
5 mM LCAHA) and significantly lower proportion of cells in G0/
G1 phase (down to 24%). At the same time, around 44% of
BrdU cells treated with DMSO left G0/G1 phase and entered
the S phase, while treatment with LCAHA significantly and
dose-dependently inhibited this transition down to 20% at
5 mM concentration of the compound (Figure 1F, bottom three
panels). These results reveal a much stronger G0/G1 arrest
than suggested by a simple analysis of the whole population
of the cells (Figure 1C). The complete outcome of the test,
presenting the progress of the cell cycle with 3-h intervals, is
presented in Figure S2.
LCAHA-Induced G0/G1 Arrest Is Accompanied by
Decreased Expression of Cyclin D1
The progression from G1 to S phase relies largely on the expres-
sion and activity of D cyclins. To verify whether the observed
impairment in cell-cycle progression following LCAHA treatment
is associated with D cyclins, we investigated the expression of
cyclins D1 and D3 in HCT116 p53wt and HCT116 p53/ cells.
A significant, dose-dependent decrease of cyclin D1 expression
was observed in both cell lines treated with 5 or 20 mM LCAHA;
however, this effect was more evident in HCT116 p53wt cells
(Figure 2A). LCA did not affect the expression of cyclin D1, and
Table 2. Effects of Lithocholic Acid and Its Derivatives on Cell Viability and on the Enzymatic Activity of USP2a
Compound
Cell Lines Data: MTT Assay USP2a Activity: Enzyme Assay
HCT116wt HCT116 p53/ Ub-AMC Assay Di-Ub Assay
LD50 (mM) GI50 (mM) LD50 (mM) GI50 (mM) IC50 (mM) IC50 (mM)
LCA 46.8 ± 2.6 – 37.4 ± 3.8 – 31.1 ± 3.4 32.0 ± 3.2
CGG >50 – >100 – not active >100
LCACNa 28.0 ± 0.7 – 29.9 ± 3.2 – 7.4 ± 1.2 13.9 ± 2.3
LCAE 23.2 ± 0.0 – 24.4 ± 0.4 – 5.8 ± 0.7 3.3 ± 0.1
LCAGLY >100 – >100 – >50 >50
LCAK >50 – >50 – 32.0 ± 1.8 33.1 ± 3.2
LCAMEa 20.5 ± 1.1 – 35.1 ± 4.8 – >50 >50
LCAMRa 8.2 ± 0.7 – 7.9 ± 0.7 – >100 >100
LCANH2 24.5 ± 0.9 – 41.8 ± 2.7 – 27.9 ± 1.0 16.7 ± 1.3
LCAHA 27.8 ± 3.9 0.87 ± 0.09 26.5 ± 0.1 0.96 ± 0.29 9.7 ± 1.5 3.7 ± 0.8
TCAS >50 – >100 – not active >100
UDCA >50 – >100 – not active >100
NSC 632839 – – – – 39.1 ± 6.4 >50
aCompounds for which solubility problems were encountered in either the cell line experiment or the enzymatic assay.
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LCAE, which did not present a biphasic effect on the survival
of HCT116 cells, decreased the expression of the protein in
HCT116 p53wt cells, but this effect was much weaker than for
LCAHA (Figure 2A). A 24-hr treatment with any of the com-
pounds did not affect the expression of cyclin D1 in HCT116
cell lines (Figure S3B).
The expression of cyclin D3was significantly increased in both
HCT116 p53wt and HCT116 p53/ cells treated with LCA, but
the treatment with LCAE or LCAHA had no effect on the expres-
sion of cyclin D3 (Figures 2A and S3A). Also, the expression of
p27, a negative regulator of cyclins, was not altered by LCA,
LCAE, or LCAHA (Figures 2A and S3A).
The treatment of HCT116 p53wt cells with LCA, LCAE, or
LCAHA for 24 or 48 hr did not induce the expression of proteins
encoded by p53-target genes (MDM2 and p21) or alter the
expression of the p53 protein itself (Figure S3B). This suggests
that up to 20 mM concentration, the effect of the tested com-
pounds on the HCT116 growth is independent of p53.
Cyclin D1 Is Crucial for the Activity of LCAHA
To verify the importance of cyclin D1 for the activity of LCAHA,
we tested an additional three cell lines: breast adenocarcinoma
cell line MCF-7 (cyclin D1 dependent [Grillo et al., 2006]), osteo-
sarcoma cell line U-2 OS (cyclin D1 positive), and osteosarcoma
Figure 1. LCAHA Inhibits the Growth of HCT116 Cells
(A) MTT assay. The cells were seeded at low confluence and treated with indicated compounds for 6 days. Cell viability was assayed by MTT. The p53 status of
tested cells is indicated. See also Figure S1.
(B) LDH release assay was performed following 48 hr of treatment. The data are presented as a percentage of total LDH activity in the treated cells lysed with
Triton X-100.
(C) The activity of caspases 3 and 7 wasmeasured in HCT116 p53wt cells treated with LCAHA or staurosporine for the indicated time periods. The graphs present
the results normalized to cell numbers at the time of caspase activity testing and then to DMSO-treated controls.
(D–F) The analysis of cell cycle was performed onHCT116 p53wt (D [left panel], E, and F) andHCT116 p53/ (D, right panel) cells treatedwith DMSOor LCAHA for
48 hr and pulse-labeled with BrdU. The cells were harvested or cultured for additional 9 hr in the absence of BrdU. The cells were stained with FITC-conjugated
anti-BrdU antibody and propidium iodide (PI), and analyzed by flow cytometry for cell-cycle distribution (D and F) or BrdU incorporation (E). (F) The analysis of cell-
cycle distribution was performed separately for BrdU+ (blue) and BrdU (black) populations of cells. For the detailed description of the experiment, see also
Figure S2.
All graphs showmean values ± SD from three independent experiments. Statistical significancewas evaluated using one-way ANOVAwith Tukey’s post hoc test:
*p < 0.05, **p < 0.01, ***p < 0.001.
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cell line SAOS-2 (cyclin D1 negative). For MCF-7 and U-2 OS
cells, treatment with LCAHA resulted in a biphasic, dose-depen-
dent decrease of viability, similar to the result observed for
HCT116 cells (Figure 2B). In the case of SAOS-2 cells, the
viability decrease was observed only at high concentrations of
compound (Figure 2B). LCA was much less active for all three
cell lines (LD50 > 50 mM). For both MCF-7 and U-2 OS cell lines
a significant decrease of cyclin D1 expression was observed
following LCAHA treatment, while the expression of cyclin D1
was not observed in SAOS-2 cells (Figure 2C). In addition a col-
ony-forming assay was performed on cyclin D1-addictedMCF-7
cells and cyclin D1-negative SAOS-2 cells. LCAHA treatment did
not affect the clonogenic potential of SAOS-2 cells, while for the
MCF-7 cells a significant decrease of the clonogenic potential
was observed, as revealed by analysis of the surviving fraction
and mean colony size (Figures 2D and 2E).
To additionally assess the importance of cyclin D1 for the
activity of LCAHA, we knocked down the expression of cyclin
D1 in the HCT116 p53wt using small interfering RNA (siRNA)
technology, and treated the cells with LCAHA. Analysis of
cell-cycle progression was performed following double stain-
ing with the PI- and FITC-conjugated anti-BrdU antibody, as
described above. The knockdown of cyclin D1 was verified
with western blotting (Figure 3, left panel).
In the absence of cyclin D1 the growth of HCT116 cells was
reduced by around 30% (not shown). However, at the time of
the analysis (72 hr post transfection) the progression through the
cell cycle was similar for both the knocked down cyclin D1 and
control cells (Figure 3, DMSO-treated cells: samples 1–4). Appar-
ently, the cells adapt to cyclin D1 deprivation as described previ-
ously (Sherr andRoberts, 2004). In fact, cyclinD1knockdownwas
assisted by the decreased expression of p27, whichmay improve
the cycling of cyclin D1-deprived cells (Figure 3, left panel).
Treatment with LCAHA blocked the cell-cycle progression of
the control siRNA-transfected HCT116 cells (Figure 3, compare
sample 6 with sample 2). Importantly, the knockdown of cyclin
D1 partially restored normal cycling of the cells treated with
LCAHA. In the absence of cyclin D1 significantly more of the
LCAHA-treated BrdU cells entered the S phase, and signifi-
cantly more of the LCAHA-treated BrdU+ cells finished the cell
cycle, compared with the cells with normal cyclin D1 expression
(Figure 3, compare samples 8 and 6).
LCAHA Antagonizes the Mitogenic Environment
Cyclin D1 is a key modulator of the transition through the G1/S
checkpoint and is known to be sensitive to proliferative signals
delivered by the mitogens. To evaluate the interplay between
the mitogens provided by the serum and LCAHA, we per-
formed a synchronization-release assay on the cells treated
with LCAHA. To assess the involvement of cyclin D1 in this inter-
play, we used MCF-7 (cyclin D1-dependent) and SAOS-2 (cyclin
D1-negative) cells. The cells were synchronized in G0/G1 by the
removal of fetal bovine serum (FBS) for 2 days of the culture in
the presence of LCAHA. After this time, the cells were released
by the addition of medium containing 10% FBS for 24 hr (still
in the presence of the compound).
Serum starvation resulted in an increase of the proportion of
cells in G0/G1 phase at the expense of the S phase, while the
addition of serum resulted in a gross entry into the S phase for
both cell lines treated with DMSO, as expected (Figure S4).
Pre-treatment with LCAHA significantly inhibited the entry into
the S phase in MCF-7 but not in SAOS-2 cells (Figure S4). This
result confirms that LCAHA blocks the proliferative signals
delivered by serum and suggests the involvement of cyclin D1
in this phenomenon.
LCAHA Lowers Cyclin D1 Half-Life Despite Increased
Phosphorylation of Akt and GSK-3b
The presence of serum provides proliferative signals by acti-
vating ERK and AKT signaling pathways, which increase the
expression of cyclin D1 (Tari and Lopez-Berestein, 2000). ERK
activation induces de novo synthesis of cyclin D1 (Chambard
et al., 2007), while AKT is involved in cyclin D1 stabilization
by alleviating a destabilizing impact of GSK-3b kinase (Diehl
et al., 1998).
To characterize the mechanism of cyclin D1 downregulation
by LCAHA, we first examined the level of CCND1 mRNA. In the
three cell lines, i.e., HCT116, MCF-7, and U-2 OS, CCND1
mRNA was detected, but its level did not change after the treat-
ment with LCAHA (Figure 4A). In SAOS-2 cells CCND1 mRNA
was not detected.
We then verified the stability of cyclin D1 in LCAHA-treated
HCT116 cells. The cells were treated for 48 hr with DMSO or
5 mM LCAHA, and cycloheximide (CHX) was applied for the
last 15–60 min of the treatment. The half-life of the protein was
significantly decreased (p = 0.025) from 40.6 ± 2.4 min in the
DMSO-treated cells to 25.3 ± 2.0 min in LCAHA-treated cells
(Figures 4B and 4C).
To assess the involvement of AKT pathway in the observed
decrease of cyclin D1 stability, we monitored the phosphoryla-
tion of Akt kinase and its direct target GSK-3b along with the dy-
namics of cyclin D1 decay in HCT116 p53wt cells. The cells were
Figure 2. The Involvement of Cyclin D1 in the Growth-Inhibitory Effect of LCAHA
(A) HCT116 p53wt (left panel) or HCT116 p53/ (right panel) cells were treated with DMSO (markedwith D), or 5 or 20 mM tested compounds for 48 hr, followed by
western blot analysis. The graphs present densitometry analysis of cyclin D1 expression and showmean ± SEM from three independent experiments. Statistical
significance was evaluated using one-way ANOVA with Tukey’s post hoc test: *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S3.
(B) For the MTT assay the cells were seeded at low confluence and treated with tested compounds for 6 days. The graphs show mean values ± SD from three
independent experiments.
(C) Analysis of cyclin D1 and p21 expression in the cells treated with DMSO or 10 mM LCAHA for 48 hr. The graph presents densitometry analysis of cyclin D1
expression and shows mean ± SEM from three independent experiments. For the statistics, a t test was performed: *p < 0.05, **p < 0.01.
(D) Colony formation assay was performed onMCF-7 or SAOS-2 cells treated with DMSO or 5 mMLCAHA for 5 days. The photographs are representative of three
experiments.
(E) The numbers and sizes of the colonies formed in the colony formation assay (D) were measured using ImageJ software. Based on these data, the surviving
fraction and relative mean colony size was calculated for the LCAHA-treated cells. The graphs showmean ± SE values from three experiments. For the statistics,
a t test was performed: **p < 0.01; n.s., not significant.
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treated for 24, 26, 28, 30, or 32 hr with LCAHA or DMSO. A sig-
nificant decrease in cyclin D1 was observed over the time course
of the experiment (Figures 4D and 4E). Surprisingly, this was
accompanied by an increase of the phosphorylation of both
Akt andGSK-3b, which unexpectedly suggests a positive impact
of the AKT pathway on cyclin D1 protein stability (Figures 4D
and 4E).
LCA and Its Derivatives Inhibit the Activity of USP2a
In 2009 Shan and colleagues demonstrated that USP2a deubi-
quitinase stabilizes cyclin D1 by removing ubiquitin moieties,
thus protecting the protein from proteasomal degradation
(Shan et al., 2009). To verify the engagement of USP2a in the ac-
tion of LCAHA, we first looked at the expression of two other
known targets of USP2a deubiquitinase: Aurora A (Shi et al.,
2011) and cyclin A1 (Kim et al., 2012). HCT116 cells were treated
for 48 hr with DMSO or LCAHA at two concentrations, 5 mM and
20 mM. A significant decrease of the expression level was
observed for both evaluated proteins following LCAHA treatment
(Figure 4F). This observation supports the notion that LCAHA
inhibits USP2a in HCT116 cells.
To verify the cell line data, we tested in vitro the ability of LCA
and its derivatives to directly inhibit USP2a activity in Ub-AMC
hydrolysis and FRET (fluorescence resonance energy transfer)
Di-Ub K63-2 assays. An active, histidine-tagged USP2a catalytic
domain was pre-incubated with various concentrations of LCA
and its derivatives for 30 min and the rate of hydrolysis of sub-
strates was measured. Both assays yielded comparable results.
LCA and its five derivatives inhibited USP2a with IC50 values in
the range 2–37 mM (Table 2). The most potent compounds,
LCAE and LCAHA, exhibited IC50 values in a one-digit micro-
molar range (Table 2 and Figures 5A–5C). The IC50 values deter-
mined for LCACN are similar to those for LCAE and LCAHA,
although because of the observed solubility problems these
values are not reliable. The remaining compounds showed low
or no activity.
For comparison, previously described deubiquitinase (DUB)
inhibitor NSC 632839 was tested in Ub-AMC and Di-Ub K63-2
assays yielding IC50 values of 39.1 ± 6.4 mM and above 50 mM,
respectively (Figure S5A). This was in agreement with the
previously reported EC50 value of 45 ± 4 mM (Nicholson
et al., 2008).
To additionally verify the binding of LCAE and LCAHA to
USP2a, we performed a fluorescence-based thermal shift assay
(Pantoliano et al., 2001). In this assay the interaction with small-
molecule ligands induces a thermal stabilization of the protein,
Figure 3. Cyclin D1 Knockdown Renders HCT116 Cells Resistant to LCAHA
HCT116 p53wt cells were transfected with the cyclin D1 siRNA or control siRNA, followed by treatment with 5 mM LCAHA or DMSO as a control, as presented on
the scheme at the top of the figure. Silencing of the cyclin D1 expression was verified 48 hr following treatment (72 hr following transfection) by western blotting
(left panel). At the same time, the cells were pulse-labeled with BrdU and immediately harvested (time point ‘‘t0’’) or cultured for an additional 9 hr (time point
‘‘t0+9h’’). The cells were stained with the PI- and with FITC-conjugated anti-BrdU antibody and analyzed by flow cytometry. BrdU
+ and BrdU cells were analyzed
separately for cell-cycle distribution usingModFit LT software. The dot-plot graphs show the representative results of two experiments, and the bar graphs show
mean ± SD from these experiments. The samples indicated with the black rectangles were analyzed for statistically significant differences using the t test: *p <
0.05, **p < 0.01. See also Figure S4.
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which is observed as a change in the protein melting point pro-
portional to the affinity of the molecule (Matulis et al., 2005).
Themeasuredmelting temperature of USP2a protein was rela-
tively low, with a Tm value of 35.4
C (Figure 5D). LCAE and
LCAHA increased the melting point of USP2a by 4.6C (Tm
40.0C) and 1.8C (Tm 37.2C), respectively (Figure 5D). The
data confirm the interaction of tested compounds with the pro-
tein. Furthermore, the results show that LCAE exhibits better af-
finity to USP2a compared with LCAHA, in agreement with our
in vitro enzyme activity assays.
To characterize the mode of action of LCAHA, we studied
the kinetics of USP2a inhibition by performing Ub-AMC assay
at varied substrate and inhibitor concentrations. The kinetics
constants were determined using a linear regression curve
fitting to the double reciprocal Lineweaver-Burk plot (Figure 5E).
The determined Vmax values decreased significantly with the
Figure 4. Impact of LCAHA on the Expression and Stability of Cyclin D1
(A) The expression of cyclin D1-encoding mRNA (CCND1) was evaluated by RT-PCR. The cells were treated with DMSO or 10 mM LCAHA for 48 hr.
(B and C) The cells were treated with DMSO or LCAHA for 48 hr, and cycloheximide (CHX) was added for the last 15–60 min, followed by western blot analysis of
cyclin D1 expression. The graph in (C) presents densitometry analysis of the expression level of cyclin D1 (B) and shows mean ± SEM values from three inde-
pendent experiments. The statistical significance was evaluated using a t test on mean t1/2 values from these three experiments.
(D and E)Western blot analysis of the expression of cyclin D1, phospho-Akt, and phospho-GSK-3b in HCT116 p53wt cells after the treatment with 5 mMLCAHA for
the indicated time periods. (D) Western blot images from the representative experiment. (E) Densitometry analysis of the expression level of cyclin D1,
P-Akt(S473), and P-GSK-3b(S9) normalized to a-tubulin. The graphs show mean ± SD from three independent experiments. Statistical significance was eval-
uated using a t test: *p < 0.05, **p < 0.01.
(F) HCT116 cells were treated with DMSO (marked with D), or 5 or 20 mM LCAHA for 48 hr, followed by western blot analysis of the expression of Aurora A and
cyclin A1. The graphs present densitometry analysis of the proteins’ expression and show mean ± SEM from three independent experiments. Statistical sig-
nificance was evaluated using one-way ANOVA with Tukey’s post hoc test: *p < 0.05, **p < 0.01.
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increasing concentration of LCAHA, while Km values remained
unchanged (Figure 5F and Table S1), suggesting a non-compet-
itive mode of inhibition.
LCAE and LCAHA Are Selective Inhibitors of USP
Proteins
To test the selectivity of LCA and its most potent derivatives
LCAE and LCAHA, we tested the inhibition of USP7 protein activ-
ity in a Ub-AMC assay. LCA showed no inhibition, while LCAHA
and LCAE demonstrated a selective inhibition of USP2a protein
at the concentration of 10 mM (Figure 5G).
In addition, we tested the activity of LCAE and LCAHA toward
a panel of DUBs using a mass spectrometry-based high-
throughput enzyme activity assay (Ritorto et al., 2014). In the
experiment 32 DUB enzymes belonging to three separate fam-
ilies were used: ubiquitin-specific proteases (USPs, 19 proteins),
ovarian tumor proteases (OTUs, 11 proteins), and JAMM/MPN+
(2 proteins).
For both compounds the inhibition of a subset of DUB en-
zymes was observed. Similarly to our previous experiments,
LCAHA presented lower activity than LCAE (Figures S5B and
S5C). The analysis of the impact of the compounds on three
separate DUB families, USPs, OTUs, and JAMM/MPN+ proteins,
revealed a significant selectivity of LCAHA and LCAE toward
USP proteins (Figure S5D, p = 0.0006 for LCAHA and p =
0.0022 for LCAE). Besides the two exceptions for both LCAHA
and LCAE (i.e., A20 and TRABID for LCAHA, and VCPIP1 and
OTULIN for LCAE), the activity of OTU enzymes was much less
affected by the compounds than the activity of USP enzymes.
The activity of neither AMSH nor AMSH-LP, both belonging to
JAMM/MPN+ family, was inhibited by the two tested com-
pounds. This indicates that the compounds show selectivity
toward USP enzymes, and confirm that USP2 is among the
enzymes most potently inhibited by the compounds.
DISCUSSION
Bile acids are considered promising scaffolds for the design
of antitumor compounds. In the present study, we describe
the synthesis and characteristics of several LCA derivatives,
including LCAHA, which demonstrated a unique ability to selec-
tively inhibit the growth of cyclin D1-expressing cell lines. The GI
activity of LCAHA was not associated with the induction of ne-
crosis or apoptosis, as demonstrated by the analysis of the ac-
tivity of caspases 3 and 7 and LDH release. Instead, an inhibition
of cell growth was observed at a non-toxic concentration range
of 0.5–15 mM in cyclin D1-expressing, but not cyclin D1-nega-
tive cells.
Cyclin D1 was reported to function as an oncoprotein,
providing the cancer cell not only with the advantage of
mitogen-independent proliferation but also modulation of pro-
cesses such as angiogenesis and DNA-damage response (Bart-
kova et al., 1995;Musgrove et al., 2011). In normal cells cyclin D1
is a short-lived protein with a half-life of around 30 min (Diehl
et al., 1997). Its stability is tightly regulated bymultiple cellular ki-
nases, including protein kinase GSK3b, which phosphorylates
cyclin D1, targeting the protein to proteasomal degradation
(Alao, 2007; Diehl et al., 1998). The activity of GSK3b is inhibited
by the Akt kinase-driven phosphorylation, activated in response
to mitogenic stimuli. The treatment of HCT116 cells with LCAHA
significantly decreased the half-life of cyclin D1, suggesting that
LCAHA affects the mechanism of cyclin D1 degradation. Inter-
estingly, instead of AKT pathway inhibition we observed an
increased phosphorylation of both Akt and GSK3b kinases,
suggesting a cyclin D1-stabilizing rather than -destabilizing envi-
ronment (Shimura et al., 2012).
In 2009 a novel component regulating cyclin D1 expression
was described by Shan et al., who identified USP2a deubiqui-
tinase as an enzyme responsible for cyclin D1 stabilization.
Our biochemical analysis demonstrated that LCA and its de-
rivatives inhibit USP2a activity. The decreased expression
level of two other USP2a targets, namely Aurora A and cyclin
A1, confirmed the inhibition of USP2a by LCAHA in the cells.
LCA itself was a relatively weak inhibitor of USP2a in the
in vitro DUB activity assay. Replacing the hydroxyl groups at
positions R1 and R4 with methyl acetate or amine moieties
(LCAE and LCAHA, respectively) strongly improved the po-
tency of the tested compounds in USP2a inhibition. LCAE
demonstrated the best USP2a inhibition in biochemical assay,
but no GI properties in cell-based assay. We hypothesize that
this was due to the partial hydrolysis of an ester bond in the
cellular environment, leading to the release of LCA, which
was inactive in the inhibition of cell growth. The introduction
of larger substituents at position R4, and additional hydroxyl
Figure 5. Effect of Selected Compounds on USP2a Activity
(A) Ub-AMC hydrolysis assay demonstrates that LCAHA inhibits USP2a enzymatic activity. USP2a catalytic domain was incubated with the substrate and
increasing concentrations of LCAHA and the fluorescence signal were measured during the time course of the experiment. The graph shows representative data
of three or more repeats. See also Figure S5.
(B) Dose-response inhibition of USP2a activity measured in the Ub-AMC hydrolysis assay in the presence of various concentrations of LCA and its derivatives
LCAE and LCAHA. The graph shows mean ± SD values from three independent experiments. See also Figure S5.
(C) Di-Ub K63-2 hydrolysis assay demonstrates that LCAHA inhibits USP2a capability to hydrolyze the isopeptide bond between two ubiquitin molecules. The
graph shows representative data of three or more repeats.
(D) LCA derivatives induce thermal stabilization of USP2a, as monitored by thermal shift assay. The graph presents the effect on USP2a thermal stabilization in
the presence of 50 mM LCAE or LCAHA.
(E) Kinetic analysis of the USP2a-catalyzed hydrolysis of Ub-AMC substrate in the presence of the LCAHA. The reciprocal initial velocities are plotted versus
the reciprocal substrate concentrations (Lineweaver-Burk plot). The graphs show mean ± SD values from three independent experiments.
(F) Vmax and Km values determined by fitting the Lineweaver-Burk equation. Kinetic constants trends are characteristic for the non-competitive inhibition model.
The graphs show mean ± SD values from three independent experiments. Statistical significance was evaluated using one-way ANOVA with Tukey’s post hoc
test: **p < 0.01. See also Table S1.
(G) The inhibition of USP2a and USP7 enzymes by the LCA, LCAE, and LCAHA compounds in the Ub-AMC assay. The graphs present percent inhibition of the
proteins’ activity in the presence of compounds at 10 mM and show mean ± SD values from three independent experiments. See also Figure S5.
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groups in positions R2 and R3, resulted in low or no activity of
the compounds.
To date, three distinct classes of small-molecule inhibitors of
USP2a have been reported: NSC 632839 (Nicholson et al.,
2008), chalcones (Issaenko and Amerik, 2012), and the com-
pound ML364 (Davis et al., 2016), with activities at one- or
two-digit micromolar concentrations. Of note, the first two clas-
ses of the inhibitors are covalent, cysteine-reactive electrophiles,
while the latter is a non-covalent inhibitor but with the exact
mechanism of action unknown. For LCAHA, the analysis of the
kinetics of Ub-AMC hydrolysis by USP2a revealed a decrease
in Vmax and no change in Km values. These trends are character-
istic for a non-competitive inhibition model, which assumes that
the inhibitor interacts with the enzyme at a location other than the
active site, resulting in the slowing down of the reaction rate.
Cyclin D1 acts in concert with p27 in regulating cell-cycle pro-
gression in dividing cells (Sa et al., 2005). In our study, the treat-
ment with LCAHA markedly decreased the expression of cyclin
D1 while the expression of p27 was unchanged. This causes
an increased p27/cyclin D1 ratio, which has been reported to
prolong G1 phase and promote G0/G1 cell-cycle arrest (Sa
et al., 2005; Stacey, 2010). Accordingly, we observed G0/G1 ar-
rest in HCT116 cells treated with the compound.
Along with G0/G1 arrest, a slower progression through the S
phase was observed in LCAHA-treated cells, which obviously
masked the real extent of G0/G1 arrest. It seems that the combi-
nation of G0/G1 arrest and slower progression through the S
phase together contribute to the prolongation of the cell cycle,
resulting in cell-growth inhibition observed in a non-toxic con-
centrations of LCAHA.
While the G0/G1 arrest is a clear consequence of a decreased
cyclin D1/p27 expression ratio, the inhibition of the rate of DNA
synthesis may be confusing (Fukami-Kobayashi and Mitsui,
1999). However, decreased cyclin D1 in G1 phase may have
two consequences, which may affect the time required for
DNA duplication. First, cyclin D1 is required for the expression
of cyclin E, which participates in the initiation of DNA synthesis
(Coverley et al., 2002; Jackson et al., 1995). Indeed, our results
show that low cyclin D1 expression is accompanied by low cyclin
E1. Second, cyclin D1 was shown to sequester inhibitory p27
protein from the complexes of cyclin E1 with Cdk2. Therefore,
the decreased cyclin D1 level may provide more p27 for the inhi-
bition of cyclin E1/Cdk2 complexes, thus additionally disabling
the activity of the already depleted cyclin E1 (Cheng et al.,
1998). Although the study of the cyclin D1 knockdown presented
herein suggests at least partial engagement of cyclin D1 in both
described effects, some further hints on themechanism of the in-
hibition of DNA synthesis could include LCAHA impact on other
deubiquitinases or the degradation of other USP2a-targets,
which is currently the focus of our studies.
The analysis of the activity of LCAHA and LCAE toward 32
DUB enzymes from three families revealed significant specificity
of the compounds toward USPs, including USP2a. We are
currently exploring the structural features of USPs, which deter-
mine the observed specificity. Based on our kinetic studies the
compounds are not expected to bind at the active site of
USP2a, but since only the catalytic domain of USP2a was
used in our biochemical assays, the compounds bind to this
domain of the USPs. Therefore, our study of the specificity of
LCA derivatives toward DUB enzymes may ultimately lead to
specific non-competitive inhibitors in the future.
In previous studies, the toxic and pro-apoptotic properties of
LCA derivatives have been reported to be beneficial for the elim-
ination of cancer cells (Goldberg et al., 2011; Katona et al., 2009;
Ma´jer et al., 2014; Sharma et al., 2010; Singh et al., 2015). These
studies, however, did not decipher the molecular targets with a
single exception whereby LCA was shown to activate p53
through antagonizing MDM2 and MDMX (Vogel et al., 2012).
Notably, in our experiments performed at relatively low concen-
trations of LCA and its derivatives, no effect on p53 activity was
found. This was shown by testing the expression of proteins en-
coded by p53-regulated genes p21 and MDM2, as well as the
expression of p53 itself. The tested compounds demonstrated
similar dose-response curves regardless of p53 status in the
HCT116 cell line. Therefore, it seems that at concentrations up
to 20 mM the effect of the tested compounds on cell growth is
p53 independent.
In summary, we show that cell-growth inhibition induced by
LCAHA is accompanied by a significant decrease in cyclin D1
level,which is a consequenceof decreasedstability of theprotein.
We also show that LCAHA antagonizes proliferative signals deliv-
eredby thepresenceof serum in the culturemediumanddescribe
the mechanism of engagement of USP2a protein in the observed
destabilization of cyclin D1 by LCAHA. Our work constitutes a
starting point for the design of more potent USP inhibitors based
on an LCA scaffold for improved treatment of cancer.
SIGNIFICANCE
Cytotoxic properties of lithocholic acid (LCA) have been
utilized in multiple approaches aimed at the discovery of
antitumor drugs. Structure optimization of LCA led to the
discovery of molecules with improved anticancer proper-
ties, active at low-micromolar concentrations. In the present
study, we report for the first time the discovery of an LCA de-
rivative that effectively inhibits cell growth at submicromolar
concentrations. We also propose that this activity is a result
of a direct inhibition of USP2a deubiquitinase, leading to a
significant decrease of the level of cyclin D1, a crucial regu-
lator of cell-cycle progression. Our discovery shows that
LCA derivatives are promising future therapeutics for the
treatment of cyclin D1-dependent cancers. This study con-
stitutes a starting point for the design of USP inhibitors
based on an LCA scaffold to provide novel opportunities
for cancer treatment.
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STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
FITC-conjugated anti-BrdU antibody BioLegend Cat# 364104 RRID:AB_2564481
rabbit polyclonal anti-cyclin D1 Santa Cruz Biotechnology Cat# sc-753 RRID:AB_2070433
mouse monoclonal anti-Cyclin D3 Cell Signaling Technology Cat# 2936 RRID:AB_2070801
polyclonal anti-p53 Santa Cruz Biotechnology Cat# sc-6243 RRID:AB_653753
rabbit monoclonal anti-p21 Cell Signaling Technology Cat# 2947 RRID:AB_823586
rabbit monoclonal anti-p27 Cell Signaling Technology Cat# 3686 RRID:AB_2077850
mouse monoclonal anti-Cyclin A2 Cell Signaling Technology Cat# 4656 RRID:AB_2071958
mouse monoclonal anti-Cyclin E1 Cell Signaling Technology Cat# 4129 RRID:AB_2071200
rabbit monoclonal anti-p-Akt(S473) Cell Signaling Technology Cat# 4060 RRID:AB_2315049
rabbit monoclonal anti-p-GSK-3b(S9) Cell Signaling Technology Cat# 5558 RRID:AB_10013750
mouse monoclonal anti-Aurora A Santa Cruz Biotechnology Cat# sc-373856 RRID:AB_10988868
rabbit polyclonal anti-cyclin A1 Santa Cruz Biotechnology Cat# sc-7252 RRID:AB_1562274
rabbit monoclonal anti-GAPDH Cell Signaling Technology Cat# 2118 RRID:AB_561053
rabbit monoclonal anti-a-Tubulin Cell Signaling Technology Cat# 2125 RRID:AB_2619646
goat peroxidase-conjugated anti-rabbit Cell Signaling Technology Cat# 7074 RRID:AB_2099233
horse peroxidase-conjugated anti-mouse Cell Signaling Technology Cat# 7076 RRID:AB_330924
Bacterial and Virus Strains
One Shot BL21(DE3) Chemically Competent/E. coli/ Invitrogen (Thermo Fisher Scientific) Cat#C600003
Chemicals, Peptides, and Recombinant Proteins
THIAZOLYL BLUE TETRAZOLIUM BROMIDE, MTT Sigma Aldrich Cat#M5655-1G; CAS: 298-93-1
Dimethyl sulfoxide, DMSO, Hybri-Max (for cell
treatment and cryopreservation)
Sigma Aldrich Cat#D2650-5X10ML; CAS: 67-68-5
5-Bromo-20-deoxyuridine (BrdU) BioUltra,R99% Sigma Aldrich Cat#B9285-50MG; CAS: 59-14-3
Staurosporine Santa Cruz Biotechnology Cat# sc-3510 A; CAS: 62996-74-1
Propidium Iodide (PI) Serva Cat#33671.01; CAS: 25535-16-4
Hoechst 33342 Thermo Fisher Scientific Cat#62249; CAS: 23491-52-3
RIPA buffer Sigma Aldrich Cat#R0278-50ML
Protease inhibitor cocktail Sigma Aldrich Cat#P8340-5ML
Phosphatase inhibitor cocktail Roche Cat#04 906 845 001
Albumin, Bovine, Fraction V. Heat Shock
Isolation (BSA)
BioShop Cat#ALB001.250
Clarity Western ECL Substrate BioRad Cat#1705061
Lipofectamine 2000 Life Technologies Cat#11668-027
Renozol GenoPlast Biochemicals Cat#BMGPB1100-2
M-MLV Reverse Transcriptase Promega Cat# M1701
Hydroxylamine solution 50 wt. % in H2O Sigma Aldrich Cat# 438227; CAS: 7803-49-8
Lithocholic acid Sigma Aldrich Cat# L6250; CAS: 434-13-9
Glycine Sigma Aldrich Cat# 410225; CAS: 56-40-6
Ammonium hydroxide solution Sigma Aldrich Cat# 09859; CAS: 13550-49-7
4-(2-Aminoethyl)morpholine Sigma Aldrich Cat# A55004; CAS: 2038-03-1
Acetyl chloride Sigma Aldrich Cat# 320129; CAS: 75-36-5
Chromium(VI) oxide Sigma Aldrich Cat# 675644; CAS: 1333-82-0
Morpholine Sigma Aldrich Cat# 394467; CAS: 110-91-8
Isobutyl chloroformate Sigma Aldrich Cat# 177989; CAS: 543-27-1
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
DIC Sigma Aldrich Cat# D125407; CAS: 693-13-0
Chloroform-d Armar Cat# 013300.2040; CAS: 865-49-6
DMSO-d6 Armar Cat# 015600.2035; CAS: 2206-27-1
Sulfuric acid POCH Cat# 575000115; CAS: 7664-93-9
Acetic acid POCH Cat# 568760421; CAS: 64-19-7
Methanol POCH Cat# 621990426; CAS: 67-56-1
Dichloromethane POCH Cat# 628410421; CAS: 75-09-2
TEA POCH Cat# 848930423; CAS: 121-44-8
Acetonitrile POCH Cat# 102640111; CAS: 75-05-8
Sodium Bicarbonate POCH Cat# 810530115; CAS: 144-55-8
Sodium Sulfate Anhydrous POCH Cat# 807870111; CAS: 7727-73-3
LB BROTH (MILLER) BioShop Cat#LBL407.5
IPTG , Reagent Grade, min 99% BioShop Cat#IPT002.25; CAS: 367-93-1
Phenylmethanesulfonyl fluoride (PMSF) Sigma Aldrich Cat#P7626; CAS: 329-98-6
Chelating Sepharose Fast Flow GE Healthcare Cat#17057502
Q Sepharose Fast Flow GE Healthcare Cat#17051001
Ubiquitin-AMC VIVA Bioscience Cat#VB2906-0050
Di-Ubiquitin K63-2 LifeSensors Cat#DU6302
NSC-632839 LifeSensors Cat#SI9689; CAS: 157654-67-6
SYPRO Orange Protein Gel Stain Thermo Fisher Scientific Cat#S6650
vector pGEX-6p-1 GE Healthcare Cat#28-9546-48
PreScission Protease GE Healthcare Cat# 27-0843-01
Recombinant USP2 (258-605) This paper N/A
Recombinant Ubiquitin (1-76) This paper N/A
Recombinant USP7 (208-561) This paper N/A
DUB enzymes and ubiquitin for MALDI TOF
High Throughput DUB Activity Assay
(Ritorto et al., 2014) N/A
Critical Commercial Assays
CytoTox-ONE Homogeneous Membrane
Integrity Assay
Promega Cat# G7891
Caspase-Glo 3/7 Assay Promega Cat# G8091
GoTaq qPCR Master Mix Promega Cat# A6001
Experimental Models: Cell Lines
Human: HCT116 ECACC Cat# 91091005, RRID:CVCL_0291
Human: U-2 OS ECACC Cat# 92022711, RRID:CVCL_0042
Human: SAOS-2 ECACC Cat# 89050205, RRID:CVCL_0548
Human: MCF-7 ECACC Cat# 86012803, RRID:CVCL_0031
Oligonucleotides
Human cyclin D1 siRNA Santa Cruz Biotechnology Cat# sc-29286
siRNA-A Santa Cruz Biotechnology Cat# sc-37007
siRNA-B Santa Cruz Biotechnology Cat# sc-44230
siRNA-C Santa Cruz Biotechnology Cat# sc-44231
Oligo-dT:
TTTTTTTTTTTTTTT
Genomed N/A
RT PCR CCND1 mRNA primer 1:
TGCCAACCTCCTCAACGACCG
This paper N/A
RT PCR CCND1 mRNA primer 2:
TCGCAGACCTCCAGCATCCAG
This paper N/A
RT PCR GAPDH mRNA primer 1:
TGCACCACCAACTGCTTAGC
Genomed ; (Yin et al., 2001) N/A
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Lukasz
Skalniak (lukasz.skalniak@uj.edu.pl).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
Human colorectal carcinoma cell lines HCT116 p53wt and HCT116 p53-/-, and human osteosarcoma cell lines U-2 OS and SAOS-2
were cultured inMcCoy’smedium supplementedwith 10%Fetal Bovine Serum (FBS) (BioWest). Human breast adenocarcinoma cell
line (female) MCF-7 was cultured in DMEM medium supplemented with 10% FBS.
The cell lines were routinely verified for mycoplasma infection using a PCR-based method (van Kuppeveld et al., 1992).
METHOD DETAILS
Cell Viability MTT Assay
For MTT assay, the cells were seeded on 96-well transparent plates and treated the next day with the compounds or DMSO for
6 days. Thiazolyl Blue Tetrazolium Bromide (MTT, Sigma Aldrich) was added for 60 minutes to a final concentration of 500 ng/ml.
The medium was removed and MTT crystals were dissolved in isopropanol supplemented with 40 mM HCl. The absorbance was
measured with Infinite 200 microplate reader (Tecan Group Ltd.) at 570 nm with the reference wavelength 650 nm for background
subtraction.
Membrane Integrity LDH Release Assay
Membrane integrity LDH release assay was performed using CytoTox-ONE kit (Promega). The cells were seeded on 96-well black
plates, and after 24 hours treated with the compounds or DMSO for 2 days. The assay was performed according to the manufac-
turer’s instructions. For each well the data was calculated as a % of total LDH content, measured for the lysed cells, treated in
the same manner as cells on that well.
Continued
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RT PCR GAPDH mRNA primer 2:
GGCATGGACTGTGGTCATGAG
Genomed; (Yin et al., 2001) N/A
Mycoplasma detection primer 1:
GPO-1: ACTCCTACGGGAGGCAGCAGTA
Genomed; (van Kuppeveld
et al., 1992)
N/A
Mycoplasma detection primer 2:
MGSO: TGCACCATCTGTCACTCTGTTAACCTC
Genomed; (van Kuppeveld
et al., 1992)
N/A
USP7 (208-561) primer forward:
GCTACTCGAGTTACTATTCCTGCCGCTCC
Genomed N/A
USP7 (208-561) primer reverse:
GCAAGGATCCAAGAAGCACACAGGCTAC
Genomed N/A
Recombinant DNA
pet16b-UB (1-76, human) Prof. Stefan Jentsch, Max Planck
Institute for Biochemistry, Munich,
Germany; (Beers and Callis, 1993)
N/A
pet24a-USP2 (258-605, human) Prof. Tad Holak, Max Planck
Institute for Biochemistry, Munich,
Germany; (Renatus et al., 2006)
N/A
human USP7 ORF BioScience OCABo5050A1122D
pGEX-6p-1-USP7 (208-561, human) This paper N/A
Software and Algorithms
ModFit LT Software v4.1.7 Verity Software House http://www.vsh.com/products/mflt/
index.asp
Image Lab v5.0 BioRad http://www.bio-rad.com/en-us/
product/image-lab-software
ImageJ 1.48v Schneider et al., 2012 https://imagej.nih.gov/ij/
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Cell Cycle Analysis
The cells were treated with DMSOor LCAHA for 48 hours and pulse-labelled with 10 mMbromodeoxyuridine (BrdU, Sigma Aldrich) for
the last hour of the treatment. After that, the cells were either harvested by trypsinization and fixed with 96% ethanol, or cultured for
additional 3-9 hours in the absence of BrdU before harvesting and fixation. The cells were stained with PI and FITC-conjugated anti-
BrdU antibody (BioLegend, cat. 364104) and analysed with Fortessa flow cytometer (Becton Dickinson). Cell cycle distribution was
analysed using ModFit LT Software (Verity Software House).
Caspase 3/7 Activity
The cells were plated on the 96-well white, flat bottom plates (Falcon) and treated with DMSO, LCAHA or Staurosporine. For the
detection of caspase activity Caspase-Glo 3/7 Assay System was used (Promega) according to the manufacturer’s instructions.
Due to the observed growth-inhibitory properties of LCAHA the results were normalized to cell numbers, calculated from the pictures
of Hoechst-stained cells seeded on transparent culture plates and treated identically as the cells seeded for caspase activity assay
(mean nuclei number per picture was 6452 for 3 days treatment with DMSO, and 3957, 4229 and 2783 for the cells treated with
increasing concentrations of LCAHA).
Western Blotting
Total cell lysates were prepared with RIPA buffer (Sigma Aldrich) containing protease inhibitor cocktail (Sigma Aldrich) alone or with
phosphatase inhibitor cocktail (Roche). Following the electrophoresis and transfer, PVDF membranes were blocked with 4% BSA
(BioShop) in TBS-N buffer and incubated with primary antibody at 4C overnight. After four washes, the addition of secondary an-
tibodies and additional four washes, the detection was performed using Clarity Western ECL Substrate (BioRad) and ChemiDoc
MP system (BioRad). The densitometry analysis was performed with Image Lab software (BioRad). All measured values, besides cy-
clin D1 stability experiment, were normalized to GAPDH or a-tubulin expression level.
The following antibodies and dilutions were used: rabbit polyclonal anti-cyclin D1 (1:200, Santa Cruz Biotechnology (SCBt), cat.
sc-753), mouse monoclonal anti-Cyclin D3 (1:1 000, Cell Signaling Technology (CST), cat. 2936), polyclonal anti-p53 (1:200,
SCBt, cat. sc-6243), rabbit monoclonal anti-p21 (1:1 000, CST, cat. 2947), rabbit monoclonal anti-p27 (1:1 000, CST, cat. 3686),
mousemonoclonal anti-Cyclin A2 (1:1 000, CST, cat. 4656), mousemonoclonal anti-Cyclin E1 (1:1 000, CST, cat. 4129), rabbit mono-
clonal anti-p-Akt(S473) (1:1 000, CST, cat. 4060), rabbit monoclonal anti-p-GSK-3b(S9) (1:1 000, CST, cat. 5558), mousemonoclonal
anti-Aurora A (1:100, SCBt, cat. sc-373856), rabbit polyclonal anti-cyclin A1 (1:200, SCBt, cat. sc-7252), rabbit monoclonal anti-
GAPDH (1:4 000, CST, cat. 2118), rabbit monoclonal anti-a-Tubulin (1:4 000, CST, cat. 2125), goat peroxidase-conjugated anti-rabbit
(1:2 000, CST, cat. 7074), horse peroxidase-conjugated anti-mouse (1:2 000, Cell Signaling, cat. 7076).
Colony Formation Assay
For the colony formation assayMCF-7 or SAOS-2 cells were treated with DMSO or 5 mMLCAHA for 5 days. One thousand of the cells
was then seeded on 6-well plates and cultured for 2-4 weeks until the generation of well-visible clones. The plates were stained with
crystal violet, imaged with the ChemiDoc MP system and analyzed using the ImageJ software (Schneider et al., 2012) and ‘Analyze
particles’ tool. The surviving fraction (SF) was calculated using the equation: SF = (PE of treated sample / PE of control) * 100%, where PE
(plating efficiency) = Ncolonies / Ncells plated.
siRNA Transfection
HCT116 cells were seeded on 6-well plates and transfected the next day with Lipofectamine 2000 (Life Technologies) and 100 pmol
of siRNA according to the manufacturer’s instructions. No medium change was performed following the transfection. The following
siRNA products were used: cyclin D1 siRNA (h): sc-29286 and the mixture of three negative control siRNA sequences: siRNA-A,
siRNA-B and siRNA-C (Santa Cruz).
RT PCR
Total RNAwas isolatedwith Renozol (GenoPlast Biochemicals) according to themanufacturer’s instructions. Five hundred ng of RNA
was reverse-transcribed using M-MLV RT (Promega) and oligo-dT primer. RT PCR was performed with the use of GoTaq qPCR
Master Mix (Promega) and the following primers: for CCND1 mRNA: TGCCAACCTCCTCAACGACCG and TCGCAGACCTCCAG
CATCCAG, forGAPDHmRNA: TGCACCACCAACTGCTTAGC and GGCATGGACTGTGGTCATGAG (Yin et al., 2001). The hybridiza-
tion step was carried out at 60C and the program involved 30 amplification cycles. The products were separated on 1% agarose gel
and visualized with ChemiDoc MP system.
USP2a Expression and Purification
HumanUSP2a (residues 258-605) was expressed in the Escherichia coli BL21 (DE3, Invitrogen). Cells were grown in LBmedium con-
taining 100 mg/ml ampicillin at 37 C and induced with 0.5 mM IPTG at OD600 of 0.7-0.9 and cultured for additional 5 h at 37 C. Cells
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were harvested by centrifugation and frozen at -20 C. USP2a purification was carried out according to optimized protocol (Renatus
et al., 2006). In brief, cells from 6 liters culture were resuspended in 300ml of lysis buffer (10 mMTris/HCl pH=8.0, 1mMMgCl2, 5 mM
b-mercapthoetanol, 10 mMPMSF) and ruptured by sonication. After centrifugation supernatant was loaded on aChelating Sepharose
Fast Flow (GE Healthcare) charged with nickel ions. The column was washed with lysis buffer and protein was eluted with lysis buffer
supplemented with 250 mM imidazole. Fractions containing USP2a were combined and further purified on Q-Sepharose Fast Flow
(GE Healthcare) column. USP2 protein was in the flow-through fraction.
The last purification step consisted of size exclusion chromatography on HiLoad 16/60 Superdex 75 prep grade (GE Healthcare)
in PBS pH=7.4 containing 5 mM DTT. USP2a was stored for further experiments as 0.01 mM protein stock with 10% glycerol
at -80 C.
Ubiquitin Expression and Purification
Escherichia coli BL21 (DE3, Invitrogen) was transformed with pet16b-UBwt (1-76, human) and grown in LB medium containing
100 mg/ml ampicillin at 37 C. Protein expression was induced with 1 mM IPTG at OD600 of 0.7-0.9 and cultured for additional 6 h
at 37 C. Cells were harvested by centrifugation and frozen at -20 C. Ubiquitin purification was carried out according to optimized
protocol (Beers and Callis, 1993). In brief, cells from 4 liters culture were resuspended in 200 ml of lysis buffer (50 mM NaH2PO4
pH=8.0, 300 mM NaCl, 1 mM imidazole) containing 1 mg/ml lysozyme. After incubation of cells on ice (10 min), NaCl and PMSF
were added to final concentrations 600 mM and 2 mM, respectively. Cells were raptured by sonication. Cleared supernatant was
loaded on a Chelating Sepharose Fast Flow (GE Healthcare) charged with nickel ions. The column was subsequently washed
with lysis buffer, lysis buffer without NaCl, lysis buffer adjusted to pH=5.5 and pH=4.5. Protein was eluted with lysis buffer supple-
mented with 250 mM imidazole.
As the last purification step size exclusion chromatography on HiLoad 16/60 Superdex 75 prep grade (GE Healthcare) equilibrated
with PBS pH=7.4 was used. Ubiquitin was stored for further experiments at 0.5-2 mM concentration at -20 C.
USP7 Expression and Purification
HumanUSP7 catalytic domain (residues 208-561) was cloned into the pGEX-6P-1 vector (GEHealthcare) and expressed in the E. coli
BL21 (DE3, Invitrogen). Cells were grown in LB medium containing 100 mg/ml ampicillin at 37 C and induced with 0.5 mM IPTG at
OD600 of 0.7-0.9 and cultured overnight at 16
C. Cells were harvested by centrifugation. Next cells were resuspended in buffer A
(50 mM Tris/HCl pH 9.0, 50 mM NaCl, 3 mM b-mercapthoetanol) and disrupted by sonication. Cell lysate were clarified by centrifu-
gation (45 000 g, 40min.) and dialyzed against buffer A. Supernatant was loaded onto Q-Sepharose column and proteins were eluted
with NaCl gradient. Fractions containing GST fused USP7were combined, concentrated and dialyzed against buffer (50mMTris/HCl
pH 7.0, 50 mM NaCl, 3 mM b-mercapthoetanol). During dialysis protein was digested with PreScission Protease (GE Healthcare).
USP7 protein and cleaved GST were separated on Mono Q HR 10/10 column (GE Healthcare). The last purification step consisted
of size exclusion chromatography on HiLoad 16/60 Superdex 75 prep grade (GE Healthcare) in 50 mM Tris/HCl, 150 mM NaCl,
2 mM DTT.
Ub-AMC and Di-Ub K63-2 Hydrolysis Assays
For ubiquitin substrate hydrolysis assays human recombinant USP2a catalytic domain (residues 258-605) was used. The assays
were performed using Infinite 200 PRO – Tecan plate reader and 96-well, black Greiner microplates in a 100 ml reaction volume.
Ub-AMC-hydrolysis assay was performed in a reaction buffer (50 mM Tris/HCl, pH=7.5, 1 mMEDTA, 1 mMMgCl2). USP2a (10 nM)
was preincubated with an excess of tested compound for 30 minutes and fluorescence changes were recorded at excitation and
emission wavelengths of 355 nm and 460 nm respectively, immediately after Ub-AMC (500 nM, Viva Biosience) addition.
Di-Ub K63-2 hydrolysis assay was performed in 50 mM Tris/HCl pH=7.5, 1mM DTT. USP2a (20 nM) was preincubated with an
excess of tested compound for 30 min. Fluorescence changes were recorded at excitation and emission wavelengths of 540 nm
and 580 nm respectively, immediately after Di-Ub (200 nM, LifeSensors) addition.
The excess of the wild type ubiquitin or NSC 632839 was used in both assays as the inhibition control. All assays were performed
simultaneously in triplicate and results are presented as mean values ± SD.
Thermal Shift Assay (TSA)
TSA analysis was carried out bymonitoring the fluorescence of SYPROOrange Dye (Life Technologies) in the presence of USP2a and
tested compounds at increasing temperatures (form 22 to 98oC). Experiments were performed in PBS pH=7.4 buffer. USP2a (1 mM)
was incubated alone and with LCAE or LCAHA compounds (both at 50 mM). Constant temperature gradient was applied (0.2C/min)
and fluorescence changes were monitored using real time thermocycler (BioRad). Melting temperature (Tm) was estimated from the
first derivative of fluorescence intensity as a function of temperature.
MALDI TOF Based High Throughput DUB Activity Assay
The assay was performed as described before (Ritorto et al., 2014). Thirty one human DUBs were freshly diluted in reaction buffer
(40mM Tris–HCl, pH 7.6, 5mM DTT, 0.005% BSA) to the proper concentrations. Enzymes were incubated with the LCAHA and
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LCAE at 100 mM final concentration for 30 min at room temperature. Diubiquitin topoisomers (K63, K48, K11 and M1) were diluted to
0.2 ml/mg and added to the reaction mixture using a Nanoliter pipetting system (Mosquito LabTech) to the final concentration of
1.5 mM. The plate was sealed and incubated for 30 min at room temperature and stopped by adding TFA to a final concentration
of 2% (v/v). The terminated reaction was then transferred (1.050 ml) to a 384 plate (LSVD, TTP Labtech), spiked with 15N-ubiquitin
internal standard (0.15 ml, 16 mM) and mixed 1:1 with 2.5 DHAP matrix freshly prepared (7.6 mg of 2,5 DHAP in 375 ml ethanol
and 125 ml of an aqueous 12 mg/ml diammonium hydrogen citrate). The resulting matrix/reaction mixture was spotted in 200 ml
aliquots onto an MTP AnchorChip 1,536 TF (600 mm anchor, Bruker Daltonics).
Mass spectrometry data was acquired on an UltrafleXtreme MALDI-TOF mass spectrometer (Bruker Daltonics) with Compass 1.3
control and processing software. The sample carrier was taught before each analysis to optimize and centre laser shooting. Internal
calibration was performed before each analysis using the 15N-Ub peak [M+H]+ average = 8,569.3). Samples were analyzed in auto-
matic mode (AutoXecute, Bruker Daltonics) as previously reported (Ritorto et al., 2014). For area calculation, the complete isotopic
distribution was taken into account. An in-house made script was used to report - 15N and mono-ubiquitin areas; plotting of graphs,
calculation of standard deviation and coefficient of variation (%) were processed in Microsoft Excel.
Compound Synthesis and Characterization
3-hydroxylithocholanamide (LCANH2)
Lithocholic acid (200 mg, 0.53 mmol) was dissolved in DCM (7 ml) and TEA (0.3 ml). The solution was cooled to 0oC and isobuthyl
chloroformate (190 ml, 1.45 mmol) was added dropwise. The mixture was stirred for 15 min at 0oC and cold 25% ammonium hydrox-
ide was added slowly until the white precipitate stopped forming. The crude product was filtered off and dried under vacuum and
crystalized from methanol to give (160 mg 0.43 mmol) (80% yield) as white needles, mp 216-219oC. IR (ATR): 3453, 3382, 3189,
2933, 2867, 1667 cm-1. 1H NMR (300 MHz, CDCl3) d = 0.61 (s, 3H, CH3), 0.85-0.89 (m, 6H), 0.91-1.25 (m, 11H), 1.25-1.42 (m, 7H),
1.43-1.57 (m, 2H), 1.57-1.72 (m, 3H), 1.72-1.85 (m, 2H), 1.85-1.99 (m, 2H), 1.99-2.12 (m, 1H), 3.35-3.44 (m, 1H), 4.45 (d, J
4.45 Hz, 1H), 6.64 (s, 1H, NH), 7.22 (s, 1H, NH). 13C NMR (75 MHz, CDCl3) d = 11.9, 18.3, 20.4, 23.3, 23.8, 26.2, 26.9, 27.7, 30.4,
31.4, 32.1, 34.2, 35.0, 35.2, 35.4, 36.3, 40.0, 41.5, 42.3, 55.6, 56.1, 69.9, 174.7 (CONH2). HRMS (ESI) calcd for C24H41NO2:
398.3035; found: 398.3030 [M+Na]+.
1H NMR of compound LCANH2 (300 MHz, DMSO-d6):
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13C NMR of compound LCANH2 (75 MHz, DMSO-d6):
N-(3-hydroxylithocholanolyl)glycine (LCAGLY)
Lithocholic acid (500 mg, 1.33 mmol) and methyl glycinate hydrochloride (164 mg, 1.31 mmol) were dissolved in 3 ml of anhydrous
DCM at 0oC and TEA (325 ml, 2.33 mmol) was added. The mixture was stirred for 15 minutes, after which DIC (271 ml, 1.38 mmol) was
dropped. The reaction was left overnight at RT and then was diluted with 10 ml of DCM, washed with 1M HCl, brine and dried over
anhydrous Na2SO4. Solvent was removed under reduced pressure and the resulting compound was purified by flash column chro-
matography (DCM) and recrystallized from ethanol/water as white needles. So obtained methyl N-(3-hydroxylithocholanolyl)glyci-
nate was dissolved in 20%methanol/water solution of LiOH and stirred for an hour. Solvent was evaporated under reduced pressure.
Water solution was acidified with conc. HCl and the resulting white precipitate was filtered, washed with distilled water and dried
under vacuum. The compound was recrystallized from ethanol/water giving (403 mg, 0.93 mmol) of white solid (69% yield) mp.
178-182oC. IR (ATR): 3516, 3267, 2938, 2867, 1732, 1608, 1573, 1204 cm-1. 1H NMR (300 MHz, DMSO-d6) d = 0.61 (s, 3H, CH3),
0.86-0.90 (m, 6H), 0.93-1.24 (m, 11H), 1.25-1.43 (m, 8H), 1.44-1.87 (m, 8H), 1.88-1.97 (m, 1H), 1.96-2.08 (m, 1H), 2.09-2.21
(m, 1H), 3.70 (d, 2H J 5.9 Hz), 4.19-4.63 (m, 1H), 8.07 (t, 1H J 5.8 Hz). 13C NMR (75 MHz, DMSO-d6) d = 11.9, 18.3, 20.4, 23.2,
23.8, 26.1, 26.9, 27.7, 30.4, 31.4, 32.1, 34.2, 34.9, 35.1, 35.4, 36.3, 40.0, 41.5, 42.2, 55.6, 56.1, 69.8, 144.8, 171.9 (CO-NH), 172.6
(CO-OH). HRMS (ESI) calcd for C26H43NO4: 456.3090; found: 456.3074 [M+Na]
+.
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1H NMR of compound LCAGLY (300 MHz, DMSO-d6):
13C NMR of compound LCAGLY (75 MHz, DMSO-d6):
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N-lithocholanolyl Morpholine (LCAMR)
To a suspension of lithocholic acid (100 mg, 0.26 mmol) and morpholine (21.25 ml, 0.24 mmol) in anhydrous DCM (3 ml) at 0oC, TEA
(60 ml, 0.430 mmol) was added. The mixture was cooled to 0oC and DIC (25 ml, 0.13 mmol) was added. The mixture was stirred 15mi-
nutes at 0oC, heated to RT and left overnight. The reaction was diluted with 10 ml of DCM and washed with 1M HCl, saturated
NaHCO3 and distilled water. The organic layer was dried over Na2SO4 and purified by flash column chromatography (DCM: AcOEt
10:1). Collected fractions were evaporated giving white solid (83 mg, 0.19 mmol) (70% yield) mp 133-135oC.IR (ATR): 3382, 2925,
2851, 1628, 1454 cm-1. 1H NMR (300 MHz, DMSO-d6) d = 0.61 (s, 3H, CH3), 0.86-0.91 (m, 6H), 0.92-1.25 (m, 11H), 1.26-1.40
(m, 7H), 1.44-1.88 (m, 7H), 1.89-1.96 (m, 1H), 2.11-2.25 (m, 1H), 2.25-2.40 (m, 1H), 3.35-3.44 (m, 5H), 3.48-3.60 (m, 4H), 4.38-
4.46 (m, 1H). 13C NMR (75 MHz, DMSO-d6) d = 11.8, 18.3, 20.4, 23.2, 23.8, 26.1, 26.9, 27.7, 29.1, 30.4, 30.9, 34.2, 35.0, 35.1,
35.4, 36.3, 39.7, 40.0, 41.4, 41.5, 42.3, 45.4, 55.5, 56.0, 66.1, 69.8, 171.2 (CONH). HRMS (ESI) calcd for C28H47NO3: 468.3454; found:
468.3437 [M+Na]+.
1H NMR of compound LCAMR (300 MHz, DMSO-d6):
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13C NMR of compound LCAMR (75 MHz, DMSO-d6):
N-(cyanomethyl)-3-hydroxylithocholanamide (LCACN)
Lithocholic acid (100 mg, 0.26 mmol) and aminoacetonitrile hydrochloride (24 mg, 0.26mmol) were treated in the same way as in the
synthesis of N-lithocholanolyl 4-(2-aminoethyl)morpholine. The product was purified by crystallization from n-hexan : AcOEt 2:1. As
white crystals (77 mg, 0.19 mmol) (70% yield.) mp 180-183oC. IR (ATR): 3460, 3255, 2932, 2864, 1667 cm-1. 1H NMR (600 MHz,
DMSO-d6) d = 0.61 (s, 3H, CH3), 0.86-0.88 (m, 6H), 0.89-0.93 (m, 1H), 0.96-1.11 (m, 5H), 1.12-1.25 (m, 6H), 1.31-1.39 (m, 6H),
1.47-1.55 (m, 2H), 1.57-1.64 (m, 1H), 1.65-1.70 (m, 2H), 1.75-1.83 (m, 2H), 1.90-1.94 (m, 1H), 2.01-2.07 (m, 1H), 2.13-2.18
(m, 1H), 2.38-2.40 (m, 1H), 4.08 (d, J 5.7 Hz, 2H, CH2), 4.42 (s, 1H, OH), 8.49 (t, 1H, J 5.6 Hz).
13C NMR (151 MHz, DMSO-d6) d =
11.8, 18.2, 20.4, 23.2, 23.8, 26.1, 26.9, 27.7, 30.4, 31.2, 31.8, 34.2, 34.8, 35.1, 35.4, 36.3, 41.5, 42.2, 55.5, 50.1, 69.8, 117.7
(ChN), 173.2 (CONH). HRMS (ESI) calcd for C26H42N2O2: 437.3144; found: 437.3138 [M+Na]
+.
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1H NMR of compound LCACN (600 MHz, DMSO-d6):
13C NMR of compound LCACN (151 MHz, DMSO-d6):
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Methyl 3-Hydroxylithocholanoate (LCAME)
To the suspension of lithocholic acid (500 mg, 1.33 mmol) in dry methanol (5 ml) acetyl chloride (50 ml, 0.70 mmol) was added drop-
wise. The flask with reactants was sealed with septum and stirred for 4h at RT. Then distilled water (5 ml) was added resulting in white
precipitate that was collected by filtration. Product was recrystallized from AcCN giving (434 mg, 1.11 mmol) of white crystals (90%
yield). mp 128-132oC. IR (ATR): 3516, 3329, 2933, 2861, 1732 cm-1. 1H NMR (300 MHz, DMSO-d6) d = 0.64 (s, 3H, CH3), 0.85-0.88
(m, 6H), 0.89-1.27 (m, 11H), 1.27-1.40 (m, 7H), 1.46-1.72 (m, 5H), 1.75-1.83 (m, 2H), 1.90-1.95 (m, 1H), 2.16-2.24 (m, 1H), 2.28-2.36
(m, 1H), 3.36 (s, 1H), 3.57 (s, 3H), 4.42 (d, J 4.61 Hz, 1H). 13CNMR (75MHz, DMSO-d6) d = 11.8, 18.8, 20.4, 23.2, 23.8, 26.1, 26.9, 27.7,
30.3, 30.6, 34.2, 34.8, 35.1, 35.4, 36.3, 41.5, 42.2, 51.2 (OCH3), 55.4, 56.0, 69.8, 173.7 (C=O). HRMS (ESI) calcd for C25H42O3:
413.3032; found: 413.3023 [M+Na]+.
1H NMR of compound LCAME (300 MHz, DMSO-d6):
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13C NMR of compound LCAME (75 MHz, DMSO-d6):
3-Oxo-Lithocholic Acid (LCAK)
CrO3 (200 mg, 2 mmol) was suspended in 0.2 ml of conc. H2SO4 acid and cooled to 0
oC to be diluted with 0.6 ml of cold distilled
water. So obtained Jones Reagent was dropped to the cold solution (100 mg, 2.60 mmol) of lithocholic acid in 10 ml of acetone.
Themixture was stirred in 0oC for an hour. Acetone was removed and the residue was diluted with 20ml of diethyl ether to be washed
with saturated solution of NaHCO3 and brine. Organic layer was dried over anhydrous Na2SO4 and evaporated. The crude product
was crystalized from methanol giving (64 mg, 0.171 mmol) of white crystals (65% yield). mp 120-123oC. IR (ATR): 2927, 2879, 1699,
1447, 1308 cm-1. 1H NMR (300MHz, DMSO-d6) d = 0.65 (s, 3H), 0.88 (d, J = 6.5 Hz, 3H), 0.96 (s, 3H), 1.31-1.01 (m, 10H), 1.47-1.34 (m,
4H), 1.62-1.49 (m, 2H), 1.88-1.64 (m, 5H), 1.95 (m, 3H), 2.43-2.03 (m, 3H), 2.74 (m, 1H), 11.88 (s, 1H). 13CNMR (75MHz, DMSO-d6) d =
11.8, 18.1, 20.7, 23.7, 25.2, 26.2, 27.6, 30.7, 30.7, 34.4, 34.8, 35.0, 36.4, 36.7, 41.8, 42.3, 43.5, 55.6, 174.8, 211.7. HRMS (ESI) calcd
for C24H38O3: 397.2719; found: 397.2719 [M+Na]
+.
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1H NMR of compound LCAK (300 MHz, CDCl3):
13C NMR of compound LCAK (75 MHz, CDCl3):
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3-Acetoxy-Lithocholic Acid (LCAE)
To acetyl chloride 1 ml stirred at 0oC lithocholic acid (100 mg, 0.26 mmol) was added in portions. The mixture was removed from the
ice bath and the suspension was left overnight at RT. Acetyl chloride was evaporated under reduced pressure. The residue was dried
under vacuum and recrystallized from acetic acid as a white solid 81 mg (90% yield), mp 168-172oC. IR (ATR): 2934, 2867, 1732,
1707 cm-1. 1H NMR (600 MHz, CDCl3) d = 0.64 (s, 3H, CH3), 0.90-0.93 (m, 6H), 1.04-1.18 (m, 5H), 1.20-1.34 (m, 6H), 1.35-1.47
(m, 6H), 1.63-1.71 (m, 1H), 1.65-1.70 (m, 1H), 1.75-1.90 (m, 5H), 1.93-1.99 (m, 1H), 2.01-2.05 (s, 3H), 2.15-2.22 (m, 1H), 2.27-2.39
(m, 1H), 4.09-4.14 (q, J 7.05 Hz, 2H ), 4.68-4.75 (m, 1H). 13C NMR (151 MHz, CDCl3) d = 12.2, 14.4, 18.4, 21.0, 21.6, 23.5, 24.3,
26.5, 26.8, 27.2, 28.3, 31.2, 31.5, 32.4, 34.7, 35.2, 35.5, 40.0, 40.3, 40.6, 42.1, 42.9, 56.2, 56.7, 60.3, 74.6, 170.8 (C=O), 174.5
(C=O). HRMS (ESI) calcd for C26H42O4: 441.2981; found: 441.2975 [M+Na]
+.
1H NMR of compound LCAE (600 MHz, CDCl3):
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13C NMR of compound LCAE (151 MHz, CDCl3):
N-(hydroxy)-3-hydroxylithocholanamide (LCAHA)
Lithocholic acid (100 mg, 0.26 mmol) and 17 ml of 50% water solution of (9 mg, 0.26mmol) hydroxylamine was treated according to
the synthesis of 3-hydroxylithocholanamide. The crude product was crystalized from methanol as white needles (68 mg, 0.17mmol)
(65% yield). mp 186-190oC. IR (ATR): 3358, 3181, 2940, 2853, 1652, 1471, 1445 cm-1. 1H NMR (300MHz, DMSO-d6) d= 0.61 (s, 3H),
0.90-0.85 (m, 6H), 1.26-0.92 (m, 11H), 1.43-1.26 (m, 7H), 1.57-1.44 (m, 2H), 1.72-1.57 (m, 3H), 1.87- 1.72 (m, 3H), 2.05-1.88 (m, 2H),
3.44-3.33 (m, 1H), 4.41 (d, J = 4.5 Hz, 1H), 8.61 (d, J = 1.2 Hz, 1H), 10.29 (s, 1H). 13C NMR (75 MHz, DMSO-d6) d= 11.9, 18.2, 20.4,
23.2, 23.8, 26.1, 26.9, 27.7, 29.2, 30.4, 31.4, 34.2, 34.8, 35.1, 35.4, 36.3, 39.7, 40.0, 41.5, 42.2, 48.6, 55.5, 56.1, 69.8, 169.5. HRMS
(ESI) calcd for C24H41NO3: 414.2984; found: 414.2984 [M+Na]
+.
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1H NMR of compound LCAHA (300 MHz, DMSO-d6):
13C NMR of compound LCAHA (75 MHz, DMSO-d6):
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QUANTIFICATION AND STATISTICAL ANALYSIS
For the comparison of three or more groups, one-way Analysis of Variance (ANOVA) with Tukey’s post-hoc test was used for the
testing of significance level. For the comparison of two groups, t test was performed.
Statistical values including the exact n and statistical significance are reported in the Figure Legends.
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